Tiziana Life Sciences – Phase 1b/2 Clinical Trial – Crohn’s Disease November 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

11th November, 2020 Tiziana Life Sciences PLC (“Tiziana” or “the Company”) Phase 1b/2 Clinical Trial – Crohn’s Disease Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease First Ever Study with take-home capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody – Potential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease -Crohn’s Disease Therapeutics Market Size $4.7 Billion by…

Tiziana Life Sciences – Initiation of Clinical Trial for COVID-19 Patients in Brazil November 2, 2020 – Posted in: Tiziana Life Sciences (TILS)

2nd November, 2020 Tiziana Life Sciences PLC (“Tiziana” or “the Company”) Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody London/New York, 2 November 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces initiation of a collaborative clinical study investigating nasally administered Foralumab either alone or in…

Tiziana Life Sciences – Demerger Update and Timetable Confirmation October 29, 2020 – Posted in: Tiziana Life Sciences (TILS)

29th October, 2020 Tiziana Life Sciences PLC (“Tiziana” or the “Company”) Demerger Update and Timetable Confirmation Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that the capital reduction required to effect the demerger of StemPrintER Sciences Limited and to enable the ultimate allotment of Accustem Sciences Limited shares (the “Demerged Shares”) to shareholders in the…

Tiziana Life Sciences October 26, 2020 – Posted in: Tiziana Life Sciences (TILS)

26th October, 2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Exercise of options, Issue of Equity PDMR Dealing and Total Voting Rights Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued 329,225 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid at a price of…

(No title) October 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

21st October, 2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Exercise of options, Issue of Equity PDMR Dealing and Total Voting Rights Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued total of 1,750,000 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid; (i) in…

Tiziana Life Sciences – Issue of Equity on Exercise of Warrants October 20, 2020 – Posted in: Tiziana Life Sciences (TILS)

20th October, 2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Issue of Equity on Exercise of Warrants Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued 35,714 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid at a price of 70 pence per share in…

Tiziana Life Sciences – Bloomberg interview September 25, 2020 – Posted in: Tiziana Life Sciences (TILS)

25th September, 2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced an interview with Dr. Kunwar Shailubhai, CEO, will air on The RedChip Money Report television program. The interview will air Sunday, 27 September 2020,…

Tiziana Life Sciences – Issue of Equity & Total Voting Rights September 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

21st September, 2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Issue of Equity and Total Voting Rights Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued 281,250 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid at a price of 128 pence per share in…

Tiziana Life Sciences – Clinical Study for September 17, 2020 – Posted in: Tiziana Life Sciences (TILS)

17/09/2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil Nasal Adminsteration of Foralumab is a potentially transformative approach for treating patients with COVID-19. New York/London, September 17, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious…

Tiziana Life Sciences – Demerger of StemPrintER – Posted in: Tiziana Life Sciences (TILS)

16/09/2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Demerger of StemPrintER and Distribution in Specie Proposed capital reduction and notice of General Meeting Tiziana Life Sciences Plc (LSE: TILS, NASDAQ: TLSA) a biotechnology company focussed on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that, following a strategic review of its clinical trial programs and core focus, it intends to demerge its StemPrintER and SPARE genomics-based personalised medicine business into a separate…

« First
1
2
3
4
5
...
11
Next
Last »